$XBI $127 -1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
$BNTX +3% pdate on Stability of COMIRNATY®: Longer Storage Possible. source
$HGEN +6% Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab. source
$ACIU +7% AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update. source
$ESPR -9% Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21. source
$PHAS +6% PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session. source
$AMRN -1% Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session. source
$IBRX +10% FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors. source
$DMAC +6% DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke.
$EVFM +2% New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021. source
$CYTK -1% Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology.
$ADMP +7% Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose. source
$MIST +1% Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21. source
$GRTX +2% Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer. source
$FHTX -1% Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286. source
$SEEL -24% Seelos Announces Positive Topline Data from the Study of SLS-002 Demonstrating a Significant Treatment Effect and a Well Tolerated Safety Profile.
$EVFM +2% Evofem Biosciences Announces Proposed Public Offering. source
$MIST +1% Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China. source
$CLVS -4% Clovis Oncology Announces At-The-Market Equity Offering Program. source
$CNCE +2% Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million. source
$LABP +1% Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets. source
Posted by DV